Feasibility of single-dose neoadjuvant pembrolizumab with subablative radiotherapy in operable breast cancer: a single-centre phase 1b/2 window-of-opportunity trial

BACKGROUND: Short preoperative immune induction could inform future breast-cancer trials, but it must not delay surgery. BreastVAX tested whether a single-dose preoperative regimen could be delivered within the planned surgical window while collecting safety and biological data. METHODS: BreastVAX (NCT04454528) was a single-centre, open-label, phase 1b/2 window-of-opportunity trial. Adults with operable invasive breast cancer scheduled for upfront surgery received one 200 mg pembrolizumab infusion alone or with one 7 Gy tumour-directed radiotherapy fraction before or after pembrolizumab. The primary phase 1b endpoint was feasibility, defined as completion of assigned preoperative treatment within 21 days without delaying surgery by more than 14 days. Phase 2 had two descriptive interim reviews. FINDINGS: In phase 1b, all six enrolled participants met the feasibility criterion. Across both phases, all 30 treated participants completed assigned preoperative therapy and underwent surgery without protocol-defined delay; median follow-up was 634 days (IQR 256-1120). Most adverse events were grade 1-2, with no deaths and no treatment-related grade 3 or higher events; the only grade 3 event was a surgical re-excision unrelated to treatment. Pathological and immune-correlative findings were exploratory and showed treatment-associated immune changes, including a neoepitope-reactive T-cell response in one responder. INTERPRETATION: Pembrolizumab, with or without a single subablative tumour-directed radiotherapy fraction, was delivered within the preoperative window without protocol-defined surgical delay. Larger biomarker-informed studies should evaluate sequence prospectively, use endpoints suited to this short regimen, and prespecify harms monitoring. FUNDING: Philanthropic support to JCT and in-kind pembrolizumab supply from Merck Pharmaceuticals.

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2026-11-16
DOI
https://doi.org/10.1016/j.ebiom.2026.106547
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Feasibility of single-dose neoadjuvant pembrolizumab with subablative radiotherapy in operable breast cancer: a single-centre phase 1b/2 window-of-opportunity trial

Angela M. DeMichele, Gary M. Freedman, Kevin R. Amses, Igor Makhlin et al.
1 links
EBioMedicine
Breast Cancer Treatment Studies
article

Feasibility of single-dose neoadjuvant pembrolizumab with subablative radiotherapy in operable breast cancer: a single-centre phase 1b/2 window-of-opportunity trial

Angela M. DeMichele, Gary M. Freedman, Kevin R. Amses, Igor Makhlin, Kaitao Li, Julia Han Noll, Neil Kanth Taunk, Kelsy C. Cotto, Sonia Ndeupen, Rachel Catherine Jankowitz, Paul W. Shafer, Joseph A. Fraietta, Andrew J. Rech, Oluwadamilola M. Fayanju, He N. Xu, Jonathan DiRusso, Susan M. Domchek, Amy Sanders Clark, Hayley Michelle Knollman, Alexander Chan Chi Huang, Bing Yi, Saveri Bhattacharya, Jack Kollmar, Frederic D. Bushman, Andy Minn, Michael Z. Mazur, J Tchou, K Li, A Nayak, Luke Keele, Robert Bartoszek, Michelle Gelman, Rong Xu, Gaorav Gupta, Jennifer L. Hope, Michael J. Malone, Payal D. Shah, Owen Koucky, Vanessa Gonzalez, Angela R. Bradbury, Evan Smith, Christina M. Bailey
article en

Abstract

BACKGROUND: Short preoperative immune induction could inform future breast-cancer trials, but it must not delay surgery. BreastVAX tested whether a single-dose preoperative regimen could be delivered within the planned surgical window while collecting safety and biological data. METHODS: BreastVAX (NCT04454528) was a single-centre, open-label, phase 1b/2 window-of-opportunity trial. Adults with operable invasive breast cancer scheduled for upfront surgery received one 200 mg pembrolizumab infusion alone or with one 7 Gy tumour-directed radiotherapy fraction before or after pembrolizumab. The primary phase 1b endpoint was feasibility, defined as completion of assigned preoperative treatment within 21 days without delaying surgery by more than 14 days. Phase 2 had two descriptive interim reviews. FINDINGS: In phase 1b, all six enrolled participants met the feasibility criterion. Across both phases, all 30 treated participants completed assigned preoperative therapy and underwent surgery without protocol-defined delay; median follow-up was 634 days (IQR 256-1120). Most adverse events were grade 1-2, with no deaths and no treatment-related grade 3 or higher events; the only grade 3 event was a surgical re-excision unrelated to treatment. Pathological and immune-correlative findings were exploratory and showed treatment-associated immune changes, including a neoepitope-reactive T-cell response in one responder. INTERPRETATION: Pembrolizumab, with or without a single subablative tumour-directed radiotherapy fraction, was delivered within the preoperative window without protocol-defined surgical delay. Larger biomarker-informed studies should evaluate sequence prospectively, use endpoints suited to this short regimen, and prespecify harms monitoring. FUNDING: Philanthropic support to JCT and in-kind pembrolizumab supply from Merck Pharmaceuticals.

EBioMedicineVol. 134
University of North Carolina at Chapel Hill (US), Parker Institute for Cancer Immunotherapy (US), Abramson Cancer Center (US), Drexel University (US), University of Pennsylvania (US)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon